Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain

Clinical Drug Investigation

Volumn 27, Issue 12, 2007, Pages 807-817

  Simpson, Kit N ^a,d   Jones, Walter J ^a   Rajagopalan, Rukmini ^b   Dietz, Birgitta ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ABBOTT GMBH AND CO KG   (Germany)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiretrovirals, therapeutic use; Atazanavir, therapeutic use; Coronary disorders; Cost effectiveness; Healthcare expenditure; HIV 1 infections; Lopinavir ritonavir, therapeutic use; Ritonavir, therapeutic use

Indexed keywords

ANTILIPEMIC AGENT; ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FRANCE; HEALTH CARE COST; HEALTH CARE QUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; ITALY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SPAIN; STATISTICAL SIGNIFICANCE; SURVIVAL; TABLET FORMULATION; UNITED KINGDOM;

EID: 36348983244     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727120-00002     Document Type: Article

References (21)

1. DeJesus E, Grinsztejn B, Rodriguez C, et al. Efficacy and safety of atazanavir (ATZ) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS AI424-045 [poster # J33 547]. 11th Conference on Retroviruses and Opportunistic Infections, 2004 Feb 8-11; San Francisco (CA)
2. Johnson M, Grinsztejn B, Rodrigues C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19 (7): 685-94
3. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J 2000; 139 (2): 273-81
4. Simpson KN, Voit EO, Goodman R, et al. Estimating the social and economic benefits of pharmaceutical innovations: modeling clinical trial results in HIV-disease. Res Hum Capital Dev 2001; 14: 175-98
5. Simpson KN, Luo MP, Chumney E, et al. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection. HIV Clin Trials 2004; 5: 294-304
6. Ghani AC, de Wolf F, Ferguson NM, et al. Surrogate markers for disease progression in treated HIV infection. JAIDS 2001; 28: 226-31
7. Ghani AC, Henley WE, Donnelly CA, et al. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001; 15: 1133-42
8. Mocroft A, Ruiz L, Reiss P, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17 (12): 1741-51
9. NORVIR prescribing information p.5-7, studies 245, 247, 432, 462 [online]. Available from URL: http://www.rxabbott.com/norvir/ 5_7_4_product_labeling.cfm [Accessed 2007 Jan 18]
10. Kaletra prescribing information p.10, study 765 [online]. Available from URL: http://www.rxabbott.com/pdf/kaletratabpi.pdf [Accessed 2007 Jan 18]
11. Castiel D, Herve C, Gaillard M, et al. Cost-utility analysis of early thrombolytic therapy. Pharmacoeconomics 1992; 1: 438-42
12. Simpson KN, Luo M, Chumney ECG, et al. Cost-effectiveness of lopinavir/ritonavir compared to atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clin Drug Invest 2007; 27: 67-74
13. Simpson KN, MacKinnon GE. Economic and clinical impact of using a PI regimen containing ATV + ritonavir vs. lopinavir-ritonavir in antiretroviral (ARV) experienced patients: modelling the lifetime impacts of the 48 week results from BMS AI424-045 [abstract no. 61235]. AIDS 2006
14. Gandjour A, Kleinsshmit F, Lauterbach KW, et al. European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001). Eur Heart J 2002; 23: 858-68
15. Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. JAIDS 2002; 31: S128-31
16. Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Pol 2006 Apr; 76 (2): 134-43
17. d'Armino A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18 (13): 1811-7
18. FDA Center for Drug Evaluation & Research. Application 21-567 Statistical Review(s) 2002 [online]. Available from URL: http://www.fda.gov/ cder/foi/nda/2003/21- 567_Reyataz_Statr.pdf [Accessed 2006 Nov 7]
19. Friis-Moller N. Exposure to PIs and NNRTI and risk of myocardial infarction: results of the D:A:D study. Session 35, Oral abstract 144, CROI 2006
20. Simpson KN, Berzon R. The health and economic costs of resistance to antiretroviral therapy [poster # 818]. 2nd IAS Conference on HIV Pathogenesis and Treatment; 2003 Jul 13-16; Paris, France
21. Simpson KN, Chumney ECG, Hicks CB, et al. Cost effectiveness of tipranavir in treatment-experienced HIV patients in the USA [ISPOR Poster]. PINIO 2006 May 20; Phildelphia (PA)